TLR7/8 agonists trigger immunostimulatory properties of human 6-sulfo LacNAc dendritic cells

Cancer Letters

Volumn 335, Issue 1, 2013, Pages 119-127

  Jähnisch, Hanka ^a   Wehner, Rebekka ^a   Tunger, Antje ^a   Kunze, Anja ^b   Oehrl, Stephanie ^b   Schäkel, Knut ^b   Rohayem, Jacques ^c   Bornhäuser, Martin ^a,d   Tonn, Torsten ^d,e   Bachmann, Michael ^a,d   Schmitz, Marc ^a,d  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c Riboxx GmbH   (Germany)

^d CENTER FOR REGENERATIVE THERAPIES DRESDEN   (Germany)

^e German Red Cross Blood Donation Service East   (Germany)

Author keywords

Dendritic cells; Imiquimod; Immunotherapy; Resiquimod; Tumor immunology

Indexed keywords

CYTOKINE; IMIQUIMOD; RESIQUIMOD; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR AGONIST;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXICITY; DENDRITIC CELL; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; NATURAL KILLER CELL; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

AMINOQUINOLINES; ANTIGENS, CD; ANTIGENS, CD86; ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; COCULTURE TECHNIQUES; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; DRUG SCREENING ASSAYS, ANTITUMOR; HLA-DR ANTIGENS; HT29 CELLS; HUMANS; IMIDAZOLES; IMMUNOGLOBULINS; IMMUNOMODULATION; INFLAMMATION MEDIATORS; K562 CELLS; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MEMBRANE GLYCOPROTEINS; T-LYMPHOCYTES; TOLL-LIKE RECEPTOR 7; TOLL-LIKE RECEPTOR 8;

EID: 84878466900     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.02.003     Document Type: Article

References (39)

1. Schön M.P., Schön M. TLR7 and TLR8 as targets in cancer therapy. Oncogene 2008, 27:190-199.
2. Craft N., Bruhn K.W., Nguyen B.D., Prins R., Lin J.W., Liau L.M., Miller J.F. The TLR7 agonist imiquimod enhances the anti-melanoma effects of a recombinant Listeria monocytogenes vaccine. J. Immunol. 2005, 175:1983-1990.
3. Ma F., Zhang J., Zhang C. The TLR7 agonists imiquimod and gardiquimod improve DC-based immunotherapy for melanoma in mice. Cell. Mol. Immunol. 2010, 7:381-388.
4. Butchar J.P., Mehta P., Justiniano S.E., Guenterberg K.D., Kondadasula S.V., Mo X., Chemudupati M., Kanneganti T.D., Amer A., Muthusamy N., Jarjoura D., Marsh C.B., Carson W.E., Byrd J.C., Tridandapani S. Reciprocal regulation of activating and inhibitory Fc{gamma} receptors by TLR7/8 activation: implications for tumor immunotherapy. Clin. Cancer Res. 2010, 16:2065-2075.
5. Drobits B., Holcmann M., Amberg N., Swiecki M., Grundtner R., Hammer M., Colonna M., Sibilia M. Imiquimod clears tumors in mice independent of adaptive immunity by converting pDCs into tumor-killing effector cells. J. Clin. Invest. 2012, 122:575-585.
6. Szeimies R.M., Gerritsen M.J., Gupta G., Ortonne J.P., Serresi S., Bichel J., Lee J.H., Fox T.L., Alomar A. Imiquimod 5% cream for the treatment of actinic keratosis: results from a phase III, randomized, double-blind, vehicle-controlled, clinical trial with histology. J. Am. Acad. Dermatol. 2004, 51:547-555.
7. Schulze H.J., Cribier B., Requena L., Reifenberger J., Ferrandiz C., Garcia D.A., Tebbs V., McRae S. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled phase III study in Europe. Br. J. Dermatol. 2005, 152:939-947.
8. Gollnick H., Barona C.G., Frank R.G., Ruzicka T., Megahed M., Tebbs V., Owens M., Stampone P. Recurrence rate of superficial basal cell carcinoma following successful treatment with imiquimod 5% cream: interim 2-year results from an ongoing 5-year follow-up study in Europe. Eur. J. Dermatol. 2005, 15:374-381.
9. Schofer H., Van Ophoven A., Henke U., Lenz T., Eul A. Randomized, comparative trial on the sustained efficacy of topical imiquimod 5% cream versus conventional ablative methods in external anogenital warts. Eur. J. Dermatol. 2006, 16:642-648.
10. Banchereau J., Briere F., Caux C., Davoust J., Lebecque S., Liu Y.J., Pulendran B., Palucka K. Immunobiology of dendritic cells. Annu. Rev. Immunol. 2000, 18:767-811.
11. Steinman R.M., Banchereau J. Taking dendritic cells into medicine. Nature 2007, 449:419-426.
12. Palucka K., Banchereau J. Cancer immunotherapy via dendritic cells. Nat. Rev. Cancer 2012, 12:265-277.
13. Gilboa E. DC-based cancer vaccines. J. Clin. Invest. 2007, 117:1195-1203.
14. Xu S., Koldovsky U., Xu M., Wang D., Fitzpatrick E., Son G., Koski G., Czerniecki B.J. High-avidity antitumor T-cell generation by toll receptor 8-primed, myeloid- derived dendritic cells is mediated by IL-12 production. Surgery 2006, 140:170-178.
15. + DC capable of inducing a Th1-type response. Eur. J. Immunol. 2007, 37:2834-2846.
16. Zhu K.J., Cen J.P., Lou J.X., Wang Q., Zhang X., Xu Y., Chen X.Z., Cheng H. Imiquimod inhibits the differentiation but enhances the maturation of human monocyte-derived dendritic cells. Int. Immunopharmacol. 2009, 9:412-417.
17. Roses R.E., Xu S., Xu M., Koldovsky U., Koski G., Czerniecki B.J. Differential production of IL-23 and IL-12 by myeloid-derived dendritic cells in response to TLR agonists. J. Immunol. 2008, 181:5120-5127.
18. 4+ T cells. J. Immunol. 2009, 182:3372-3379.
19. Schäkel K., Mayer E., Federle C., Schmitz M., Riethmuller G., Rieber E.P. A novel dendritic cell population in human blood: one-step immunomagnetic isolation by a specific mAb (M-DC8) and in vitro priming of cytotoxic T lymphocytes. Eur. J. Immunol. 1998, 28:4084-4093.
20. Schäkel K., Kannagi R., Kniep B., Goto Y., Mitsuoka C., Zwirner J., Soruri A., von Kietzell M., Rieber E. 6-Sulfo LacNAc, a novel carbohydrate modification of PSGL-1, defines an inflammatory type of human dendritic cells. Immunity 2002, 17:289-301.
21. Schäkel K., von Kietzell M., Hänsel A., Ebling A., Schulze L., Haase M., Semmler C., Sarfati M., Barclay A.N., Randolph G.J., Meurer M., Rieber E.P. Human 6-sulfo LacNAc-expressing dendritic cells are principal producers of early interleukin-12 and are controlled by erythrocytes. Immunity 2006, 24:767-777.
22. Hänsel A., Günther C., Baran W., Bidier M., Lorenz H.M., Schmitz M., Bachmann M., Dobel T., Enk A.H., Schäkel K. Human 6-sulfo LacNAc (slan) dendritic cells have molecular and functional features of an important pro-inflammatory cell type in lupus erythematosus. J. Autoimmun. 2013, 40:1-8.
23. Schmitz M., Zhao S., Schäkel K., Bornhäuser M., Ockert D., Rieber E.P. Native human blood dendritic cells as potent effectors in antibody-dependent cellular cytotoxicity. Blood 2002, 100:1502-1504.
24. Schmitz M., Zhao S., Deuse Y., Schäkel K., Wehner R., Wöhner H., Hölig K., Wienforth F., Kiessling A., Bornhäuser M., Temme A., Rieger M.A., Weigle B., Bachmann M., Rieber E.P. Tumoricidal potential of native blood dendritic cells: direct tumor cell killing and activation of NK cell-mediated cytotoxicity. J. Immunol. 2005, 174:4127-4134.
25. Wehner R., Löbel B., Bornhäuser M., Schäkel K., Cartellieri M., Bachmann M., Rieber E.P., Schmitz M. Reciprocal activating interaction between 6-sulfo LacNAc(+) dendritic cells and NK cells. Int. J. Cancer 2009, 124:358-366.
26. Hackstein H., Knoche A., Nockher A., Poeling J., Kubin T., Jurk M., Vollmer J., Bein G. The TLR7/8 ligand resiquimod targets monocyte-derived dendritic cell differentiation via TLR8 and augments functional dendritic cell generation. Cell. Immunol. 2011, 271:401-412.
27. Boullart A.C., Aarntzen E.H., Verdijk P., Jacobs J.F., Schuurhuis D.H., itez-Ribas D., Schreibelt G., van de Rakt M.W., Scharenborg N.M., de Boer A., Kramer M., Figdor C.G., Punt C.J., Adema G.J., de Vries I. Maturation of monocyte-derived dendritic cells with Toll-like receptor 3 and 7/8 ligands combined with prostaglandin E2 results in high interleukin-12 production and cell migration. Cancer Immunol. Immunother. 2008, 57:1589-1597.
28. Lehner M., Stilper A., Morhart P., Holter W. Plasticity of dendritic cell function in response to prostaglandin E2 (PGE2) and interferon-gamma (IFN-gamma). J. Leukoc. Biol. 2008, 83:883-893.
29. Napolitani G., Rinaldi A., Bertoni F., Sallusto F., Lanzavecchia A. Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat. Immunol. 2005, 6:769-776.
30. Gautier G., Humbert M., Deauvieau F., Scuiller M., Hiscott J., Bates E.E., Trinchieri G., Caux C., Garrone P. A type I interferon autocrine-paracrine loop is involved in Toll-like receptor-induced interleukin-12p70 secretion by dendritic cells. J. Exp. Med. 2005, 201:1435-1446.
31. Gorden K.B., Gorski K.S., Gibson S.J., Kedl R.M., Kieper W.C., Qiu X., Tomai M.A., Alkan S.S., Vasilakos J.P. Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8. J. Immunol. 2005, 174:1259-1268.
32. Hurst J., Prinz N., Lorenz M., Bauer S., Chapman J., Lackner K.J., von Landenberg P. TLR7 and TLR8 ligands and antiphospholipid antibodies show synergistic effects on the induction of IL-1beta and caspase-1 in monocytes and dendritic cells. Immunobiology 2009, 214:683-691.
33. Spranger S., Javorovic M., Burdek M., Wilde S., Mosetter B., Tippmer S., Bigalke I., Geiger C., Schendel D.J., Frankenberger B. Generation of Th1-polarizing dendritic cells using the TLR7/8 agonist CL075. J. Immunol. 2010, 185:738-747.
34. Stary G., Bangert C., Tauber M., Strohal R., Kopp T., Stingl G. Tumoricidal activity of TLR7/8-activated inflammatory dendritic cells. J. Exp. Med. 2007, 204:1441-1451.
35. Kalb M.L., Glaser A., Stary G., Koszik F., Stingl G. TRAIL(+) human plasmacytoid dendritic cells kill tumor cells in vitro: mechanisms of imiquimod- and IFN-alpha-mediated antitumor reactivity. J. Immunol. 2012, 188:1583-1591.
36. Moretta L., Bottino C., Pende D., Castriconi R., Mingari M.C., Moretta A. Surface NK receptors and their ligands on tumor cells. Semin. Immunol. 2006, 18:151-158.
37. Caligiuri M.A. Human natural killer cells. Blood 2008, 112:461-469.
38. Moretta A. The dialogue between human natural killer cells and dendritic cells. Curr. Opin. Immunol. 2005, 17:306-311.
39. Wehner R., Dietze K., Bachmann M., Schmitz M. The bidirectional crosstalk between human dendritic cells and natural killer cells. J. Innate Immun. 2011, 3:258-263.